EGFR and non-small cell lung carcinoma: The identification of oncogenic driver mutations and the fact that, e.g., EGFR and ALK rearrangement were clinically significant risk factors for developing BM in NSCLC patients add to a more precise selection of patients suitable for preoperative BI [39].